• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 1050936 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1413809445 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1413809445 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Stock Investors Sell Off Shares of Keryx Biopharmaceuticals, Down 2.9%

Published on Tue, 07/08/2014 - 11:39
By Mallory Stone

One of today's notable stocks in decline is Keryx Biopharmaceuticals (NASDAQ:KERX), down 2.9% to $15.16. The S&P is currently trading 0.6% lower to 1,966 and the Dow Jones Industrial Average is trading 0.7% lower to 16,912.

In the past 52 weeks, shares of Keryx Biopharmaceuticals have traded between a low of $1.28 and a high of $17.46 and are now at $15.16, which is 1,084% above that low price. In the last five trading sessions, the 50-day moving average (MA) has climbed 0.6% while the 200-day MA has risen 0.4%.

Potential upside of 59.0% exists for Keryx Biopharmaceuticals, based on a current level of $15.16 and analysts' average consensus price target of $24.10. Keryx Biopharmaceuticals shares have support at the 50-day moving average (MA) of $14.07 and additional support at the 200-day MA of $13.60.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx is developing KRX-101 (sulodexide), a novel first-in-class oral heparinold compound for the treatment of diabetic nephropathy.

By Mallory Stone
mstone@fnno.com

Latest News from FNNO

Shares of Photronics Underperformed its ...

Below are five companies in the Semiconductor Equipment industry that underperformed ye ...

Analysis of Relative Performance in the ...

Here are 5 stocks in the Retail REITs industry ranked by performance. We compiled the ...

Shares of Krispy Kreme Doughnuts Underpe...

Below are five companies in the Restaurants industry that underperformed yesterday on a ...

Bottom 5 Companies in the Residential RE...

Here are 5 stocks in the Residential REITs industry ranked by performance. We compiled ...

Shares of M&T Bank Underperformed its Pe...

Analysis was conducted on the Regional Banks industry to measure relative performance t ...

Shares of MBIA Underperformed its Peers ...

Below are five companies in the Property & Casualty Insurance industry that underperfor ...

Shares of First Majestic Silver Underper...

Here are 5 stocks in the Precious Metals & Minerals industry ranked by performance. We ...

Bottom 5 Companies in the Personal Produ...

Analysis was conducted on the Personal Products industry to measure relative performanc ...